1404559-91-6Relevant articles and documents
Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors
Wagner, Florence F.,We?wer, Michel,Steinbacher, Stefan,Schomburg, Adrian,Reinemer, Peter,Gale, Jennifer P.,Campbell, Arthur J.,Fisher, Stewart L.,Zhao, Wen-Ning,Reis, Surya A.,Hennig, Krista M.,Thomas, Méryl,Müller, Peter,Jefson, Martin R.,Fass, Daniel M.,Haggarty, Stephen J.,Zhang, Yan-Ling,Holson, Edward B.
supporting information, p. 4008 - 4015 (2016/08/23)
The structure–activity and structure–kinetic relationships of a series of novel and selective ortho-aminoanilide inhibitors of histone deacetylases (HDACs) 1 and 2 are described. Different kinetic and thermodynamic selectivity profiles were obtained by va
Inhibitors of histone deacetylase
-
Page/Page column 122; 131, (2016/09/26)
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.